Analysis of steatosis biomarkers and inflammatory profile after adding on PCSK9 inhibitor treatment in familial hypercholesterolemia subjects with nonalcoholic fatty liver disease : A single lipid center real-world experience
Copyright © 2020 The Italian Diabetes Society, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition and the Department of Clinical Medicine and Surgery, Federico II University. Published by Elsevier B.V. All rights reserved..
BACKGROUND AND AIMS: Nonalcoholic fatty liver disease (NAFLD) may be crucial in subjects with familial hypercholesterolemia (FH). We aimed to evaluate the effect of the inhibitors of proprotein convertase subtilisin/kexin type 9 (PCSK9-i) on steatosis biomarkers such as triglyceride-glucose index (TyG) and hepatic steatosis index (HSI) and analyse the role of TG/HDL in this population before and after adding-on PCSK9-i.
METHODS AND RESULTS: In this observational study, we evaluated 26 genetically confirmed FH patients with NAFLD and an LDL-C off-target despite high-intensity statins plus ezetimibe. All patients added PCSK9-i treatment and obtained biochemical analysis and TyG and HSI evaluation at baseline and after six months of PCSK9-i. No difference of steatosis biomarkers was found after adding-on PCSK9-i therapy. In a secondary analysis, we divided the study population in two groups according to TG/HDL median value: high TG/HDL group (H-TG/HDL) and low TG/HDL group (L-TG/HDL). TyG and HSI were significantly lower in the L-TG/HDL than H-TG/HDL group (for TyG 9.05 ± 0.34 vs 9.51 ± 0.32; for HSI 38.43 ± 1.35 vs 41.35 ± 1.83, p value for both < 0.05). After six months of PCSK9-i therapy, TyG and HSI were significantly reduced in the L-TG/HDL group after PCSK9-i therapy (-7.5% and -8.4% respectively, p value for both < 0.05) and these biomarkers were lower compared to H-TG/HDL group (for TyG 8.37 ± 0.14 vs 9.19 ± 0.12; for HSI 35.19 ± 1.32 vs 39.48 ± 1.33, p value for both < 0.05).
CONCLUSION: In conclusion, PCSK9-i therapy significantly ameliorate steatosis biomarkers in FH patients with low TG/HDL; our results appear to be consistent with a beneficial role of PCSK9-i on steatosis biomarkers in FH subjects with NAFLD.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
Zur Gesamtaufnahme - volume:31 |
---|---|
Enthalten in: |
Nutrition, metabolism, and cardiovascular diseases : NMCD - 31(2021), 3 vom: 10. März, Seite 869-879 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Scicali, Roberto [VerfasserIn] |
---|
Links: |
---|
Anmerkungen: |
Date Completed 17.03.2021 Date Revised 04.12.2021 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1016/j.numecd.2020.11.009 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM321099737 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM321099737 | ||
003 | DE-627 | ||
005 | 20231225175107.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2021 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1016/j.numecd.2020.11.009 |2 doi | |
028 | 5 | 2 | |a pubmed24n1070.xml |
035 | |a (DE-627)NLM321099737 | ||
035 | |a (NLM)33549441 | ||
035 | |a (PII)S0939-4753(20)30485-3 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Scicali, Roberto |e verfasserin |4 aut | |
245 | 1 | 0 | |a Analysis of steatosis biomarkers and inflammatory profile after adding on PCSK9 inhibitor treatment in familial hypercholesterolemia subjects with nonalcoholic fatty liver disease |b A single lipid center real-world experience |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 17.03.2021 | ||
500 | |a Date Revised 04.12.2021 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Copyright © 2020 The Italian Diabetes Society, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition and the Department of Clinical Medicine and Surgery, Federico II University. Published by Elsevier B.V. All rights reserved. | ||
520 | |a BACKGROUND AND AIMS: Nonalcoholic fatty liver disease (NAFLD) may be crucial in subjects with familial hypercholesterolemia (FH). We aimed to evaluate the effect of the inhibitors of proprotein convertase subtilisin/kexin type 9 (PCSK9-i) on steatosis biomarkers such as triglyceride-glucose index (TyG) and hepatic steatosis index (HSI) and analyse the role of TG/HDL in this population before and after adding-on PCSK9-i | ||
520 | |a METHODS AND RESULTS: In this observational study, we evaluated 26 genetically confirmed FH patients with NAFLD and an LDL-C off-target despite high-intensity statins plus ezetimibe. All patients added PCSK9-i treatment and obtained biochemical analysis and TyG and HSI evaluation at baseline and after six months of PCSK9-i. No difference of steatosis biomarkers was found after adding-on PCSK9-i therapy. In a secondary analysis, we divided the study population in two groups according to TG/HDL median value: high TG/HDL group (H-TG/HDL) and low TG/HDL group (L-TG/HDL). TyG and HSI were significantly lower in the L-TG/HDL than H-TG/HDL group (for TyG 9.05 ± 0.34 vs 9.51 ± 0.32; for HSI 38.43 ± 1.35 vs 41.35 ± 1.83, p value for both < 0.05). After six months of PCSK9-i therapy, TyG and HSI were significantly reduced in the L-TG/HDL group after PCSK9-i therapy (-7.5% and -8.4% respectively, p value for both < 0.05) and these biomarkers were lower compared to H-TG/HDL group (for TyG 8.37 ± 0.14 vs 9.19 ± 0.12; for HSI 35.19 ± 1.32 vs 39.48 ± 1.33, p value for both < 0.05) | ||
520 | |a CONCLUSION: In conclusion, PCSK9-i therapy significantly ameliorate steatosis biomarkers in FH patients with low TG/HDL; our results appear to be consistent with a beneficial role of PCSK9-i on steatosis biomarkers in FH subjects with NAFLD | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Observational Study | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 4 | |a Familial hypercholesterolemia | |
650 | 4 | |a NAFLD | |
650 | 4 | |a PCSK9 inhibitors | |
650 | 4 | |a Steatosis biomarkers | |
650 | 4 | |a TG/HDL | |
650 | 4 | |a esRAGE | |
650 | 7 | |a Anticholesteremic Agents |2 NLM | |
650 | 7 | |a Biomarkers |2 NLM | |
650 | 7 | |a Blood Glucose |2 NLM | |
650 | 7 | |a Cholesterol, HDL |2 NLM | |
650 | 7 | |a Cholesterol, LDL |2 NLM | |
650 | 7 | |a Hydroxymethylglutaryl-CoA Reductase Inhibitors |2 NLM | |
650 | 7 | |a Inflammation Mediators |2 NLM | |
650 | 7 | |a Lipids |2 NLM | |
650 | 7 | |a PCSK9 Inhibitors |2 NLM | |
650 | 7 | |a Serine Proteinase Inhibitors |2 NLM | |
650 | 7 | |a Triglycerides |2 NLM | |
650 | 7 | |a PCSK9 protein, human |2 NLM | |
650 | 7 | |a EC 3.4.21.- |2 NLM | |
650 | 7 | |a Ezetimibe |2 NLM | |
650 | 7 | |a EOR26LQQ24 |2 NLM | |
700 | 1 | |a Di Pino, Antonino |e verfasserin |4 aut | |
700 | 1 | |a Urbano, Francesca |e verfasserin |4 aut | |
700 | 1 | |a Ferrara, Viviana |e verfasserin |4 aut | |
700 | 1 | |a Marchisello, Simona |e verfasserin |4 aut | |
700 | 1 | |a Di Mauro, Stefania |e verfasserin |4 aut | |
700 | 1 | |a Scamporrino, Alessandra |e verfasserin |4 aut | |
700 | 1 | |a Filippello, Agnese |e verfasserin |4 aut | |
700 | 1 | |a Rabuazzo, Agata M |e verfasserin |4 aut | |
700 | 1 | |a Purrello, Francesco |e verfasserin |4 aut | |
700 | 1 | |a Piro, Salvatore |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Nutrition, metabolism, and cardiovascular diseases : NMCD |d 1997 |g 31(2021), 3 vom: 10. März, Seite 869-879 |w (DE-627)NLM090675177 |x 1590-3729 |7 nnns |
773 | 1 | 8 | |g volume:31 |g year:2021 |g number:3 |g day:10 |g month:03 |g pages:869-879 |
856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.numecd.2020.11.009 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 31 |j 2021 |e 3 |b 10 |c 03 |h 869-879 |